OCT scrutinized for neurodegenerative detecting properties

June 6, 2018
Alzheimer’s clues could be found using common eye scan.
OCT scrutinized for neurodegenerative detecting properties - Alzheimer's

Abnormal retinal changes may portend neurodegeneration indicative of Alzheimer's disease, elevating specific, high-resolution imaging routine in optometry to adjuvant status in neurological care.

Known as optical coherence tomography (OCT), the diagnostic imaging device uses light to produce a cross-sectional or three-dimensional image of the retina with micrometer resolution to detect retinal diseases such as macular degeneration, glaucoma and diabetic retinopathy. But beyond eye care, OCT continues to capture researchers' attention as a noninvasive way to examine central nervous system tissue for tell-tale signs of neurodegenerative diseases. 

In fact, numerous studies, including within the past year, suggest spectral domain-OCT (SD-OCT) might warrant further consideration in early detection and diagnosis of the sixth-leading cause of death in the United States: Alzheimer's disease. 

An irreversible and progressive degenerative brain disease, Alzheimer's currently affects 5.7 million Americans age 65 and older with projections estimating 13.8 million affected by 2050. Characterized by the buildup of beta amyloid plaques and neurofibrillary (tau) tangles in the brain that affect neurons, Alzheimer's gradually deteriorates brain tissue that affects memory, cognition and ultimately bodily functions. 

Those with Alzheimer's live an average of eight years after symptoms manifest, but survival can range 4-to-20 years, per the Alzheimer's Association. Critically, early detection and diagnosis can allow patients and caregivers time to plan, which is why SD-OCT proves promising. 

Until recently, the trademark pathology of Alzheimer's—plaque buildup and tau tangles affecting neurons—was only measurable post-mortem. But research suggesting a link between cognitive ability and retinal nerve fiber layer (RNFL) thickness, coupled with the in vivo imaging afforded by SD-OCT, could add another diagnostic tool for clinicians.   

Building upon research first presented at the Alzheimer's Association International Conference (AAIC) 2016 in Toronto that linked a thinner RNFL with poorer cognitive ability, a June 2017 study corroborated those findings. 

Published in Graefe's Archive for Clinical and Experimental Ophthalmology, the study found Alzheimer's patients had a significant reduction in global and temporal superior quadrants in peripapillary RNFL, and in superior pericentral and peripheral sectors of overall retinal thickness. Although a cross-sectional study of only 202 subjects (50 eyes of patients with mild Alzheimer's and 152 eyes of patients without), the study (when taken with the results of the aforementioned AAIC study) makes a tantalizing picture. The AAIC study of 33,000 participants found progressively thinner RNFL thickness correlated with worse cognitive recall, such that mean RNFL thickness measured 53.3 micrometers among subjects with correct recall, 52.5 micrometers among those needing two attempts, and 51.9 micrometers among those who could not recall. 

Both studies add to a catalog of evidence that OCT imaging could become a practical diagnostic tool for wide clinical deployment, as noted in a clinical review published in December 2017's Frontiers in Neurology

"With the reported colocalization of retinal (amyloid beta) and ganglion cell degeneration, a combined method to detect hallmark (amyloid beta) deposits via fundus optical imaging with assessment of structural abnormalities by OCT may prove to be a superior approach for screening at-risk populations, assessing disease progression and evaluating therapeutic efficacy," the review concludes.  

Could optometry assist with Alzheimer's?  

Although vision changes naturally occur with age and don't always indicate a more serious condition, patients 60 years and older still should be wary of age-related eye health problems that may occur without any early symptoms. Regular, comprehensive eye examinations are critical in senior years and evolving understanding of neurological health increasingly turns to ocular health as a proxy. 

Maryke Neiberg, O.D., associate dean of academic affairs at Midwestern University Chicago College of Optometry, who previously spoke with AOA Focus on optometry's role in Alzheimer's care, says patients typically do have difficulty with near-vision in the beginning stages of Alzheimer's, including crowding, alexia and figure-ground difficulties. 

"The doctor of optometry has an important role to play in the prevention and early detection of the ocular and visual changes that herald the onset of Alzheimer's disease," Dr. Neiberg wrote in a continuing education article for the California Optometric Association. "We have an even more critical role to play in the education of our patients and the public about the preventable risk factors that are associated with Alzheimer's disease."  

Related News

AOA series addresses concerns about myopia management

With the prevalence of myopia on the rise worldwide, an AOA webinar attempts to erase concern over barriers to providing myopia management. The webinar kicked off a three-event series focused on raising awareness of myopia management as a standard of care especially for children. Next is “Meet the Myopia Experts” on Saturday, June 24, at Optometry’s Meeting® 2023 in Washington, D.C.

AOA serving patients through research in optometry

For the fifth consecutive year, the AOA is sponsoring the Investigator Initiated Research Award. Investigators are invited to electronically submit proposals by July 1 for projects designed to increase knowledge through basic clinical and/or translational science relative to the continuum of eye and vision care. The AOA provides a maximum of $50,000 in direct costs for research conduct. Eric Ritchey, O.D., Ph.D., talks about his current research on low-level light therapy for patients with meibomian gland dysfunction, which can lead to dry eye disease.

Marijuana sensibilities changing fast: Are you ready for patients’ questions?

Public support for marijuana legalization has never been higher in the U.S., but evidence of its clinical utility in glaucoma care remains clouded at best.